

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/586,209
				Filing Date	January 13, 2005 (Int'l)
				First Named Inventor	Jeffrey L. SOUTHARD
				Art Unit	<del>1608</del> 1646
Examiner Name	<del>F. Sajjad</del> Ruixiang Li				
Sheet	1	of	4	Attorney Docket Number	560252000700

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	1.	US-2008/0097503-A1	04-24-2008	Creaven	
	2.	US-3,523,906	08-11-1970	Vrancken et al.	
	3.	US-3,737,337	06-05-1973	Schnoring et al.	
	4.	US-3,773,919	11-20-1973	Boswell et al.	
	5.	US-4,272,398	06-09-1981	Jaffe	
	6.	US-4,764,378	08-16-1988	Keith et al.	
	7.	US-4,797,285	01-10-1989	Barehnholz et al.	
	8.	US-4,938,763	07-03-1990	Dunn et al.	
	9.	US-4,957,119	09-18-1990	de Nijs	
	10.	US-5,019,400	05-28-1991	Gombotz et al.	
	11.	US-5,023,252	06-11-1991	Hseih	
	12.	US-5,088,505-A	02-18-1992	De Nijs	
	13.	US-5,190,761-A	03-02-1993	Liburdy	
	14.	US-5,271,961-A	12-21-1993	Mathiowitz et al.	
	15.	US-5,324,519-A	06-28-1994	Dunn et al.	
	16.	US-5,637,309-A	06-10-1997	Tajima et al.	
	17.	US-5,702,716-A	12-30-1997	Dunn et al.	
	18.	US-5,728,396-A	03-17-1998	Peery et al.	
	19.	US-5,744,153-A	04-28-1998	Yewey et al.	
	20.	US-5,863,554-A	01-26-1999	Illum	
	21.	US-5,910,482-A	06-08-1999	Yallampalli et al.	
	22.	US-5,958,877-A	09-28-1999	Wimalawansa	
	23.	US-5,985,305-A	11-16-1999	Peery et al.	
	24.	US-5,990,194-A	11-23-1999	Dunn et al.	
	25.	US-6,143,314-A	11-07-2000	Chandrashekar et al.	
	26.	US-6,201,072-B1	03-13-2001	Rathi et al.	
	27.	US-6,306,406-B1	10-23-2001	Deluca	
	28.	US-6,358,247-B1	03-19-2002	Altman et al.	
	29.	US-6,403,114-B1	06-11-2002	Rickey et al.	
	30.	US-RE37,950-E	12-31-2002	Dunn et al.	
	31.	US-6,503,534-B1	01-07-2003	Pellet et al.	
	32.	US-6,528,080-B2	03-04-2003	Dunn et al.	
	33.	US-6,544,252-B1	04-08-2003	Theeuwes et al.	
	34.	US-6,555,156-B1	04-29-2003	Loughman	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/586,209
				Filing Date	January 13, 2005 (Int'l)
				First Named Inventor	Jeffrey L. SOUTHARD
				Art Unit	1633
				Examiner Name	F. Sajjadi
Sheet	2	of	4	Attorney Docket Number	560252000700

	35.	US-6,565,874-B1	05-20-2003	Dunn et al.	
	36.	US-6,582,080-B2	06-24-2003	Gibbon et al.	
	37.	US-6,589,549-B2	07-08-2003	Shih et al.	
	38.	US-6,809,079-B2	10-26-2004	Southard et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	39.	EP-0 467 389-A2,A3	01-22-1992	University of Kentucky Research Foundation		
	40.	EP-0 645 136-A2,A3	03-29-1995	Shiseido Company Limited		
	41.	EP-0 765 659-A1	04-02-1997	Shiseido Company Limited		
	42.	EP-0 845 269-A2,A3	06-03-1998	Wo		
	43.	WO-93/23011-A1	11-25-1993	Minnesota Mining and Manufacturing Company		
	44.	WO-96/30013-A1	10-03-1996	Minnesota Mining and Manufacturing Company		
	45.	WO-03/059250-A2,A3	07-24-2003	Vasogenix Pharmaceuticals, Inc.		
	46.	WO-2005/067890-A2,A3	07-28-2005	Vasogenix Pharmaceuticals, Inc.		
	47.	WO-2005/070444-A2,A3,C1	08-04-2005	Vasogenix Pharmaceuticals, Inc.		
	48.	WO-2005/070445-A2,A3	08-04-2005	Vasogenix Pharmaceuticals, Inc.		
	49.	WO-2006/029320-A1	03-16-2006	Bayer Healthcare LLC		

Examiner Signature	/Ruixiang Li/	Date Considered	07/16/2010
-----------------------	---------------	--------------------	------------

\*EXAMINER: Initial if information considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	50.	ANAND, I.S. et al. (January 1991). "Cardiovascular and Hormonal Effects of Calcitonin Gene-Related Peptide in Congestive Heart Failure," <i>J. Am. Coll. Cardiol.</i> 17(1):208-217.	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/586,209
				Filing Date	January 13, 2005 (Int'l)
				First Named Inventor	Jeffrey L. SOUTHARD
				Art Unit	1633
				Examiner Name	F. Sajjadi
Sheet	3	of	4	Attorney Docket Number	560252000700

51.	ANONYMOUS (May 1990). <i>The FASEB Journal</i> 4(8):2544.	
52.	BENITA, S. et al. (December 1984). "Characterization of Drug-Loaded poly( <i>d,l</i> -lactide) Microspheres," <i>Journal of Pharmaceutical Sciences</i> 73(12):1721-1724.	
53.	FLEISHER, D. et al. (May 22, 1996). "Improved Oral Drug Delivery: Solubility Limitations Overcome by the Use of Prodrugs," <i>Advanced Drug Delivery Reviews</i> 19(2):115-130.	
54.	GENNARI, C. et al. (March 1990). "Improved Cardiac Performance with Human Calcitonin Gene Related Peptide in Patients with Congestive Heart Failure," <i>Cardiovascular Res.</i> 24(3):239-241.	
55.	HAEGERSTRAND, A. et al. (May 1990). "Calcitonin Gene-Related Peptide Stimulates Proliferation of Human Endothelial Cells," <i>Proc. Natl. Acad. Sci. USA</i> 87(9):3299-3303.	
56.	HUNT, S.A. et al. (2001). <u>ACC/AHA Practice Guidelines: ACC/AHA Guidelines for the Evaluation and Management Chronic Heart Failure in the Adult</u> , American College of Cardiology and the American Heart Association, Inc., ed., pp. 1-56.	
57.	International Search Report mailed on July 20, 2006, for PCT Application No. PCT/US2005/001225, filed on January 13, 2005, five pages.	
58.	KAKEYA, N. et al. (February 1984). "Studies on Prodrugs of Cephalosporins. I. Synthesis and Bbiological Properties of Glycyloxybenzoyloxymethyl and Glycylaminobenzoyloxymethyl Esters of 7 $\beta$ -[2-(2- aminothiazol-4-yl)-(Z)-2-methoxyiminoacetamido]-3- methyl-3-cephem-4- carboxylic acid," <i>Chem. Pharm. Bull.</i> 32(2):692-698.	
59.	LU, E-X. et al. (December 1996). "Calcitonin Gene-Related Peptide-Induced Preconditioning Improves Preservation with Cardioplegia," <i>Ann. Thorac. Surg.</i> 62:1748-1751.	
60.	MARCH, K.L. et al. (January 1995). "Pharmacokinetics of Adenoviral Vector-Mediated Gene Delivery to Vascular Smooth Muscle Cells: Modulation by Poloxamer 407 and Implications for Cardiovascular Gene Therapy," <i>Human Gene Therapy</i> 6(1):41-53.	
61.	MATHIOWITZ, E. et al. (1987). "Novel Microcapsules for Delivery Systems," <i>Reactive Polymers</i> 6:275-283.	
62.	MATHIOWITZ, E. et al. (1987). "Polyanhydride Microspheres as Drug Carriers. I. Hot-Melt Microencapsulation," <i>Journal of Controlled Release</i> 5:13-22.	
63.	MATHIOWITZ, E. et al. (February 20, 1988). "Polyanhydride Microspheres as Drug Carriers. II. Microencapsulation by Solvent Removal," <i>Journal of Applied Polymer Science</i> 35(3):755-774	
64.	MATHIOWITZ, E. et al. (1990). "Morphology of Polyanhydride Microsphere Delivery Systems," <i>Scanning Microscopy</i> 4(2):329-340.	
65.	MATHIOWITZ, E. et al. (May 5, 1992). "Polyanhydride Microspheres. IV. Morphology and Characterization of Systems Made by Spray Drying," <i>Journal of Applied Polymer Science</i> 45(1):125-134.	
66.	MERRIFIELD, R.B. (July 20, 1963). "Solid Phase Peptide Synthesis. I. The Synthesis of a Tetrapeptide," <i>Journal of the American Chemical Society</i> 85(14):2149-2154.	
67.	MERRIFIELD, R.B. (April 18, 1986). "Solid Phase Synthesis," <i>Science</i> 232(4748):341-347.	
68.	NIELSEN, N.M. et al. (April 1988). "Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties," <i>Journal of Pharmaceutical Sciences</i> 77(4):285-298.	
69.	ROBINSON, R.P. (January 5, 1996). "Discovery of the Hemifumarate and (alpha-L-	

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/586,209
				Filing Date	January 13, 2005 (Int'l)
				First Named Inventor	Jeffrey L. SOUTHARD
				Art Unit	1633
				Examiner Name	F. Sajjadi
Sheet	4	of	4	Attorney Docket Number	560252000700

		alanyloxy)methyl ether as Prodrugs of an Antirheumatic Oxindole: Prodrugs for the Enolic OH Group," <i>J. Med. Chem</i> 39(1):10-18.	
	70.	SHEKHAR, Y.C. et al. (April 1, 1991). "Effects of Prolonged Infusion of Human Alpha Calcitonin Gene-Related Peptide on Hemodynamics, Renal Blood Flow and Hormone Levels in Congestive Heart Failure," <i>Am. J. Cardiol.</i> 67:732-735.	
	71.	SHIMIZU, K. et al. (December 3/17, 1999). "Adrenomedullin Receptor Antagonism by Calcitonin Gene-Related Peptide (8-37) Inhibits Carotid Artery Neointimal Hyperplasia after Balloon Injury," <i>Circulation Research</i> 85:1199-1205.	
	72.	STEVENSON, R.N. et al. (December 1992). "Calcitonin Gene-Related Peptide: A Haemodynamic Study of a Novel Vasodilator in Patients with Severe Chronic Heart Failure," <i>Intl. J. Cardiol.</i> 37:407-414.	
	73.	WANG, C-Y. et al. (November 1987). "pH-sensitive Immunoliposomes Mediate Target-Cell-Specific Delivery and Controlled Expression of a Foreign Gene in Mouse," <i>Proc. Nat. Acad. Sci. USA</i> 84:7851-7855.	
	74.	WANG, C-Y. et al. (November 28, 1989). "Highly Efficient DNA Delivery Mediated by pH-sensitive Immunoliposomes," <i>Biochemistry</i> 28(24):9508-9514.	
	75.	WIMALAWANSA, S.J. (October 1996). "Calcitonin Gene-Related Peptide and Its Receptors: Molecular Genetics, Physiology, Pathophysiology, and Therapeutic Potentials," <i>Endocrine Reviews</i> 17(5):533-585.	
	76.	WIMALAWANSA, S.J. (1997). "Amylin, Calcitonin Gene-Related Peptide, Calcitonin, and Adrenomedullin: A Peptide Superfamily," <i>Critical Reviews in Neurobiology</i> 11(2-3):167-239.	
	77.	Written Opinion mailed on July 20, 2006, for PCT Application No. PCT/US2005/001225, filed on January 13, 2005, nine pages.	
	78.	ZHOU, Z-H. et al. (December 2001). "Improvement of Preservation with Cardioplegic Solution by Nitroglycerin-Induced Delayed Preconditioning is Mediated by Calcitonin Gene-Related Peptide," <i>Int. J. Cardiol.</i> 81:211-218.	

Examiner Signature	/Ruixiang Li/	Date Considered	07/16/2010
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.